Скачать или смотреть SLS Stock: Why Insiders and BlackRock are Buying Before Year-End! 🚀

Is $SLS breaking out? In this deep dive, we analyze Sellas Life Sciences ($SLS) as it approaches the pivotal Phase 3 REGAL trial final analysis. With the "Smart Money" piling in and heavyweight leadership from Celgene veteran Katherine Kalin, the data suggests something big is brewing.

We break down the $SLS technical analysis, the massive insider buys, and why BlackRock and Anson Funds are positioning themselves before the year-end results. If you’re a retail investor looking for the next potential blue-sky breakout, this due diligence (DD) is for you.

📊 What We Cover Today:
$SLS Overview.

The Katherine Kalin Factor: Why a former Celgene & McKinsey strategist is a game-changer for Sellas.

Smart Money Tracking: Deep dive into the $30M+ institutional inflows and recent insider buys.

Financial Health: Why the recent $31M warrant exercise makes dilution a low-risk factor for now.

Phase 3 REGAL Catalyst: The countdown to the 80-death event final analysis.

Technical Setup: Identifying the double bottom, the $2.48 breakout level, and my trade plan.


💡 Join the Ticker Talker Community:
If you found this analysis helpful, please Like the video and Subscribe for more institutional-grade stock research for retail investors.

What is your price target for $SLS after the REGAL data? Let me know in the comments!

#SLSStock #SellasLifeSciences #StockMarketAnalysis #BiotechStocks #Investing #TradingInsights #TickerTalker #TechnicalAnalysis #BlackRock #PennyStocks

Disclaimer: This video is for educational and entertainment purposes only. I am not a financial advisor. Investing in biotech stocks involves high risk. Please conduct your own due diligence before making any investment decisions.